MX389296B - Metodo para tratar cancer urotelial del tracto inferior. - Google Patents

Metodo para tratar cancer urotelial del tracto inferior.

Info

Publication number
MX389296B
MX389296B MX2018013432A MX2018013432A MX389296B MX 389296 B MX389296 B MX 389296B MX 2018013432 A MX2018013432 A MX 2018013432A MX 2018013432 A MX2018013432 A MX 2018013432A MX 389296 B MX389296 B MX 389296B
Authority
MX
Mexico
Prior art keywords
lower tract
urothelial cancer
treating lower
tract urothelial
antimetabolite
Prior art date
Application number
MX2018013432A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013432A (es
Inventor
Cheryl Larrivee-Elkins
Christopher Cutie
Christopher Searcy
Dennis Giesing
Purnanand Sarma
Vikas Agarwal
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of MX2018013432A publication Critical patent/MX2018013432A/es
Publication of MX389296B publication Critical patent/MX389296B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2018013432A 2016-05-06 2017-05-05 Metodo para tratar cancer urotelial del tracto inferior. MX389296B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US201762443614P 2017-01-06 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (2)

Publication Number Publication Date
MX2018013432A MX2018013432A (es) 2019-08-12
MX389296B true MX389296B (es) 2025-03-20

Family

ID=60203435

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013432A MX389296B (es) 2016-05-06 2017-05-05 Metodo para tratar cancer urotelial del tracto inferior.
MX2021013461A MX2021013461A (es) 2016-05-06 2018-11-01 Metodo para tratar cancer urotelial del tracto inferior.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013461A MX2021013461A (es) 2016-05-06 2018-11-01 Metodo para tratar cancer urotelial del tracto inferior.

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP3452053B1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR20220123317A (enExample)
CN (2) CN118453872A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL295592A (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ748252A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG11201809838VA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3370768T3 (da) 2015-11-03 2022-03-21 Janssen Biotech Inc Antistoffer som specifikt binder pd-1 og anvendelser deraf
MX2019003683A (es) 2016-10-11 2019-08-22 Agenus Inc Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos.
SG10201913998YA (en) * 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
MX2020004771A (es) 2017-11-08 2020-10-19 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
EA023156B1 (ru) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Устройство для доставки лекарств
DK2512581T3 (da) 2009-12-17 2021-03-29 Taris Biomedical Llc Implanterbar indretning med intravesikal tolerance
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
EP2600800B1 (en) 2010-08-05 2020-09-30 TARIS Biomedical LLC Ureteral stent drug delivery device and kit
BR112013019410A2 (pt) 2011-02-04 2019-09-24 Taris Biomedical Inc dispositivo implantável para liberação controlada de fármaco de solubilidade baixa
CN104470535A (zh) * 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
PL2890384T3 (pl) * 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
CA2882575C (en) 2012-08-31 2020-05-26 Dennis GIESING Drug delivery systems and methods for treatment of prostate
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
AU2014227914B2 (en) 2013-03-15 2018-05-10 Taris Biomedical Llc Drug delivery devices and methods for drug delivery
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
KR102503010B1 (ko) 2013-08-19 2023-02-24 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
CN119950539A (zh) 2014-03-06 2025-05-09 塔里斯生物医药公司 用吉西他滨来治疗膀胱癌的药物递送系统和方法
AU2015279674B2 (en) 2014-06-26 2020-07-23 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法

Also Published As

Publication number Publication date
FI3452053T3 (fi) 2023-04-12
RU2018142908A (ru) 2020-06-08
EP3452053A4 (en) 2019-12-25
NZ748252A (en) 2025-10-31
IL262746B (en) 2022-09-01
IL262746A (en) 2018-12-31
KR102435709B1 (ko) 2022-08-25
HRP20221544T1 (hr) 2023-02-17
RU2764747C2 (ru) 2022-01-20
RU2022100624A (ru) 2022-02-09
JP2022009327A (ja) 2022-01-14
JP7712055B2 (ja) 2025-07-23
SMT202300047T1 (it) 2023-03-17
ES2940227T3 (es) 2023-05-04
NZ787786A (en) 2025-10-31
WO2017193098A1 (en) 2017-11-09
US20190388338A1 (en) 2019-12-26
KR20220123317A (ko) 2022-09-06
SI3452053T1 (sl) 2023-03-31
CN118453872A (zh) 2024-08-09
IL295592A (en) 2022-10-01
SG11201809838VA (en) 2018-12-28
AU2017261371A1 (en) 2018-12-13
PT3452053T (pt) 2023-03-03
MX2021013461A (es) 2021-12-10
RU2018142908A3 (enExample) 2020-08-31
KR20190005204A (ko) 2019-01-15
SG10201913416PA (en) 2020-03-30
MX2018013432A (es) 2019-08-12
EP3452053B1 (en) 2022-12-14
NZ787824A (en) 2025-10-31
EP4209221A1 (en) 2023-07-12
JP2024028881A (ja) 2024-03-05
EP3452053A1 (en) 2019-03-13
JP2019514970A (ja) 2019-06-06
AU2017261371B2 (en) 2023-07-06
CN109475571A (zh) 2019-03-15
CA3023274A1 (en) 2017-11-09
BR112018072551A2 (pt) 2019-02-19
RS64032B1 (sr) 2023-04-28
PL3452053T3 (pl) 2023-05-08
HUE060965T2 (hu) 2023-04-28
LT3452053T (lt) 2023-02-10

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2023006304A (es) Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
MX2021013461A (es) Metodo para tratar cancer urotelial del tracto inferior.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
CL2018001226A1 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
EA201991818A1 (ru) Лечение рака
PH12017501879A1 (en) Methods for treating cancer
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА